'It's still working': More are living with cancer as era of targeted drugs takes hold

By Deena Beasley June 3 (Reuters) - Cathy Smithwick, now 67, has lived with breast cancer, and then ovarian cancer, for more ...
Morning Overview on MSN

The government just greenlit a daraxonrasib expanded-access program for pancreatic-cancer patients with the KRAS G12C mutation — opening the new targe…

For the roughly 1 to 2 percent of pancreatic-cancer patients whose tumors carry a specific genetic glitch called KRAS G12C, ...

Landmark pancreatic cancer treatment paves way for targeting other tricky tumors

The landmark success of a drug against an ‘undruggable’ cancer is spurring fresh optimism in the quest to treat seemingly ...

Actinium Presents New ATNM-400 Data in KRAS and EGFR Mutant Models at SNMMI 2026 Supporting a Mutation-Agnostic Opportunity In Non-Small Cell Lung Cancer

Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or the Company), a pioneer in the development of targeted ...
Medical Xpress

Novel immunotherapy targets common cancer mutation, offering hope for lung and prostate cancer patients

Researchers at the University of Oslo and Oslo University Hospital have developed a promising new immunotherapy targeting the CTNNB1 gene mutation associated with various aggressive cancers such as ...

Early Research Suggests a Path to Predict and Prevent Lung Cancer

Scientists have identified proteins that could signal increased lung cancer risk, as well as a drug that could reduce the ...